Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immuron Limited ( (AU:IMC) ) has provided an announcement.
Immuron reported unaudited global first-half sales of AUD$4.2 million, up 5% year-on-year, driven primarily by strong performance of its Travelan product in Australia and the United States, despite a sharp year-on-year decline in Canada following an earlier pipeline fill. Australian H1 sales rose 13% to AUD$3.3 million, supported by increased digital and social media marketing, expanded pharmacy ranging and higher Southeast Asian travel, while U.S. sales grew 17% to AUD$0.9 million on the back of enhanced Amazon presence and intensified social media and influencer campaigns. The company also accelerated the Australian launch of its new product ProIBS ahead of Christmas, securing distribution via two of the three largest pharmacy wholesalers and listings in five banner groups, positioning itself for further category reviews and potential shelf expansion in 2026. In Canada, although H1 sales were sharply lower versus the prior year due to timing of a large initial stock pipeline, quarterly sales rebounded 191% in Q2, and Immuron plans to further build Travelan brand awareness through in-store education, promotions and social media, with a key new rollout into Jean Coutu pharmacies in Quebec scheduled for the third quarter of FY26, which could significantly deepen its penetration in the Canadian market.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian-based, globally integrated biopharmaceutical company focused on over-the-counter immune supplements targeting pathogenic bacteria and their toxins in the gastrointestinal tract. Its lead product, Travelan, is marketed internationally to travelers and consumers seeking protection against GI disturbances, and the company is expanding its portfolio with new offerings such as ProIBS for digestive health, distributed through major pharmacy and retail channels in Australia, North America and other markets.
YTD Price Performance: 13.89%
Average Trading Volume: 1,271,973
Technical Sentiment Signal: Sell
Current Market Cap: A$13.39M
See more insights into IMC stock on TipRanks’ Stock Analysis page.